Haemonetics Corporation (HAE)
After hours:
| Previous Close | 87.66 |
| Open | 87.49 |
| Bid | 50.00 x 800 |
| Ask | 91.29 x 1000 |
| Day's Range | 87.49 - 91.58 |
| 52 Week Range | 70.74 - 95.26 |
| Volume | |
| Avg. Volume | 491,438 |
| Market Cap | 4.621B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 36.99 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024.
- PR Newswire
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedu
- PR Newswire
Haemonetics Corporation Completes Acquisition of Attune Medical
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device. EnsoETM is the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency (RF) cardiac ablation procedures.
